Bladder perfusion pharmaceutical composition, preparation method therefor and application thereof
US-2024398841-A1 · Dec 5, 2024 · US
US12016957B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12016957-B2 |
| Application number | US-201917297530-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 27, 2019 |
| Priority date | Nov 27, 2018 |
| Publication date | Jun 25, 2024 |
| Grant date | Jun 25, 2024 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present description relates to a method for extracting at least one substance of interest, the method comprising the following steps: —providing an admixture comprising water, a source comprising the at least one substance of interest or at least one precursor thereof, at least one surfactant and at least one lipophilic compound; —the emulsification of the admixture, leading to the formation of an emulsion; wherein the emulsion comprises: —a continuous aqueous phase; and a discontinuous lipidic phase comprising the at least one lipophilic compound, the at least one surfactant and at least one substance of interest extracted from the source during the emulsification; wherein the method further comprises the addition of at least one cryoprotectant to the admixture and the lyophilization of the emulsion.
Opening claim text (preview).
The invention claimed is: 1. A process for extracting at least one substance of interest from a source, the process comprising the following steps of: providing a mixture comprising water, at least one surfactant, at least one lipophilic compound, and a source, the source comprising the at least one substance of interest or at least one precursor thereof; and emulsifying the mixture, thereby forming an emulsion and extracting the at least one substance of interest from the source; wherein the emulsion comprises: a continuous aqueous phase; and a discontinuous lipid phase comprising the at least one lipophilic compound, the at least one surfactant, and the at least one substance of interest extracted from the source during emulsifying; wherein the source is a plant source containing at least a portion of at least one plant, an animal source containing at least one part of at least one animal, a mineral source, a prokaryote source, and/or a unicellular eukaryote source; and wherein the process further comprises adding at least one cryoprotectant to the mixture and freeze-drying the emulsion; and wherein adding at least one cryoprotectant to the mixture is performed after emulsifying the mixture, in a weight-to-volume ratio of at least 5% w/v based on the total volume of the mixture excluding the source. 2. The process of claim 1 , wherein emulsifying the mixture comprises sonicating the mixture. 3. The process of claim 1 , wherein the source is a plant source containing at least a portion of at least one plant. 4. The process of claim 1 , wherein the at least one surfactant is selected from the group consisting of Dendri-TAC type dendrimers, F i TAC n or F i TAC n type oligomers, TPGS 1000, TPGS 750M, sugar- and/or amino acid-derived surfactants, and combinations thereof. 5. The process of claim 1 , wherein emulsifying is performed by maintaining the temperature of the mixture between about 4° C. and about 60° C. 6. The process of claim 1 , wherein the duration of emulsifying is comprised between about 0.5 seconds and about 5 hours. 7. The process of claim 1 , wherein said discontinuous lipid phase is in the form of droplets of a predetermined mean diameter. 8. The process of claim 1 , wherein the at least one cryoprotectant is selected from the group consisting of polymers, amino acids, saccharide compounds, and combinations thereof. 9. The process of claim 1 , wherein the at least one lipophilic compound, the at least one surfactant, and the at least one cryoprotectant are biocompatible. 10. The process of claim 1 , further comprising a step of pretreating prior to emulsifying the mixture, wherein the step of pretreating comprises macerating the mixture at a temperature between about 20° C. and about 60° C.
Applying ultrasound · CPC title
Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying · CPC title
Extraction with lipophilic solvents, e.g. Hexane or petrol ether · CPC title
using water, e.g. cold water, infusion, tea, steam distillation or decoction · CPC title
Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.